KR20100051837A - 소아 종양의 치료 - Google Patents

소아 종양의 치료 Download PDF

Info

Publication number
KR20100051837A
KR20100051837A KR1020107004521A KR20107004521A KR20100051837A KR 20100051837 A KR20100051837 A KR 20100051837A KR 1020107004521 A KR1020107004521 A KR 1020107004521A KR 20107004521 A KR20107004521 A KR 20107004521A KR 20100051837 A KR20100051837 A KR 20100051837A
Authority
KR
South Korea
Prior art keywords
tumor
tumors
pediatric
treatment
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107004521A
Other languages
English (en)
Korean (ko)
Inventor
클라우디오 피사노
로레다나 베스치
파올로 카르미나티
Original Assignee
시구마-토우인더스트리에파아마슈우티히리유니트에스.피이.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시구마-토우인더스트리에파아마슈우티히리유니트에스.피이.에이. filed Critical 시구마-토우인더스트리에파아마슈우티히리유니트에스.피이.에이.
Publication of KR20100051837A publication Critical patent/KR20100051837A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020107004521A 2007-08-01 2008-07-03 소아 종양의 치료 Ceased KR20100051837A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07113603 2007-08-01
EP07113603.0 2007-08-01

Publications (1)

Publication Number Publication Date
KR20100051837A true KR20100051837A (ko) 2010-05-18

Family

ID=38799381

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107004521A Ceased KR20100051837A (ko) 2007-08-01 2008-07-03 소아 종양의 치료

Country Status (11)

Country Link
US (1) US8829021B2 (https=)
EP (1) EP2182951A2 (https=)
JP (2) JP5765937B2 (https=)
KR (1) KR20100051837A (https=)
CN (1) CN101784277A (https=)
BR (1) BRPI0815051A2 (https=)
CA (1) CA2694389C (https=)
EA (1) EA015933B1 (https=)
MX (1) MX2010001084A (https=)
SG (1) SG183010A1 (https=)
WO (1) WO2009015981A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2889711A1 (en) 2012-10-29 2014-05-08 Arizona Board Of Regents On Behalf Of University Of Arizona Predictive markers for polyamine inhibitor cancer therapies
WO2015195120A1 (en) 2014-06-18 2015-12-23 Arizona Board Of Regents On Behalf Of University Of Arizona Carcinoma diagnosis and treatment based on odc1 genotype
WO2016130918A1 (en) * 2015-02-12 2016-08-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating neuroblastoma
KR20260033630A (ko) 2015-10-30 2026-03-10 캔서 프리벤션 파마수티컬스, 인코포레이티드 에플로르니틴 및 설린닥, 고정된 용량 조합 제제
JP2022532766A (ja) 2019-05-17 2022-07-19 キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド 家族性腺腫性ポリポーシスを処置するための方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE216998T1 (de) * 1999-03-09 2002-05-15 Sigma Tau Ind Farmaceuti Camptothecin-derivate mit antitumor-wirkung
PT1962850E (pt) * 2005-12-21 2012-05-21 Sigma Tau Ind Farmaceuti Tratamento de tumores resistentes a drogas
EP2120948A1 (en) * 2007-02-13 2009-11-25 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives

Also Published As

Publication number Publication date
MX2010001084A (es) 2010-03-25
JP2014111653A (ja) 2014-06-19
EA015933B1 (ru) 2011-12-30
EA201070193A1 (ru) 2010-06-30
EP2182951A2 (en) 2010-05-12
CA2694389A1 (en) 2009-02-05
WO2009015981A3 (en) 2009-09-03
US8829021B2 (en) 2014-09-09
CA2694389C (en) 2016-01-19
JP2010534699A (ja) 2010-11-11
CN101784277A (zh) 2010-07-21
WO2009015981A2 (en) 2009-02-05
JP5765937B2 (ja) 2015-08-19
AU2008282024A1 (en) 2009-02-05
SG183010A1 (en) 2012-08-30
BRPI0815051A2 (pt) 2015-02-10
US20100197718A1 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
ES2811367T3 (es) Análogos de éteres fosfolipídicos como vehículos de fármacos que seleccionan como objetivo el cáncer
CN104363913B (zh) Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途
US8481553B2 (en) Antimetastatic compounds
CN1315479C (zh) 橄榄苦苷在制备抑制血管生成药物中的用途
CN101273989B (zh) 一类小檗胺衍生物及其盐的应用
CA2782555C (en) 3-(indolyl)-or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
TW202128173A (zh) 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療
US20230277522A9 (en) Methods for treating vascular malformations
KR20100051837A (ko) 소아 종양의 치료
ES2935705T3 (es) Un ligando del receptor GABA A
CN106232115A (zh) 用于治疗抗性的癌症的预防或治疗性组合物
EP3012248B1 (en) Substance having tyrosine kinase inhibitory activity and preparation method and use thereof
WO2021030404A1 (en) Methods and compositions for treating vascular malformations
US8853233B2 (en) Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives
CN110642796A (zh) 一种喹唑啉类衍生物及其应用
AU2008282024B2 (en) Treatment of pediatric tumors
HK1142810A (en) Treatment of pediatric tumors
HK40097577A (zh) 对parp抑制剂耐药的癌症的治疗剂
EA016487B1 (ru) Лечение резистентных к лекарственным препаратам опухолей

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100226

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130702

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140731

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150217

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140731

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20150325

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20150217

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20161012

Appeal identifier: 2015101001587

Request date: 20150325

B901 Examination by re-examination before a trial
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20150325

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20150325

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20140930

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20130702

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL NUMBER: 2015101001587; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20150325

Effective date: 20161012

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20161012

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20150325

Decision date: 20161012

Appeal identifier: 2015101001587